Sino Biopharmaceutical : SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE APPOINTMENT OF EXECUTIVE DIRECTOR, REDESIGNATION OF DIRECTOR AND CHANGE OF CHIEF EXECUTIVE OFFICER

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

SUPPLEMENTAL ANNOUNCEMENT

IN RELATION TO THE APPOINTMENT OF EXECUTIVE DIRECTOR,

REDESIGNATION OF DIRECTOR AND

CHANGE OF CHIEF EXECUTIVE OFFICER

Reference is made to the announcement of Sino Biopharmaceutical Limited (the "Company") dated 19 August 2020 (the "Announcement"), in relation to the appointment of executive director, redesignation of director and change of chief executive officer. Unless the context otherwise requires, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

The Board would like to provide additional information in relation to the appointment of Mr. Li Yi ("Mr. Li") as the executive director and chief executive officer of the Company as follows:

Mr. Li has extensive management experience in listed companies and a vision of international corporate operations. Mr. Li used to serve as the managing director of China Merchants Holdings (International) Company Limited (stock code: 144). Under his leadership, the company was included in the Hang Seng Index during his tenure and became the best performing constituent stock in 2004. Mr. Li was thereby selected as one of the "Most Outstanding Business Leaders in Asia" by CNBC Asia.

The successful experience in the financial field helped Mr. Li accumulate a deep understanding of international finance and capital markets. Under his leadership, UBS and J.P. Morgan, the two large international financial institutions in Europe and America, have successively established industry- leading business platforms in China. The above-mentioned experience is also a strong proof of Mr. Li's excellent organization and management ability, outstanding resource integration ability and experience in building business platforms.

1

The joining of Mr. Li, who moved from the industrial and commercial industry to the financial industry, and now back to the industrial and commercial industry, will bring effective leadership, rich capital market experience and a more international perspective to the Company, and form a powerful complement to the Company's existing management team which has extensive experience in the pharmaceutical industry. Under the strong guidance of the Board, Mr. Li will work together with the excellent management team of the Company to build a better future.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 20 August 2020

As at the date of this announcement, the Board of the Company comprises nine Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan, Ms. Li Mingqin and four Independent Non- Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.

2